BioSpace News Archive

A new study from researchers at Hospital for Special Surgery has evaluated trends in the use of total knee arthroplasty in patients under 21 in the United States.

Sofusa®, a wholly-owned division of Sorrento Therapeutics, announced that it will host a virtual Key Opinion Leader panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17, 2022 at 11:30 AM EST.

HUTCHMED Limited announces initial results from FRUTIGA, a Phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction adenocarcinoma.

SK Biopharmaceuticals announced that the state-run Korea Drug Development Fund has decided to support and finance the company’s development of SKL27969, which is being evaluated as potential treatment for patients with advanced solid tumors, widening SK Biopharmaceuticals’ area into oncology.

Akeso, Biopharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has granted Breakthrough Therapy Designation for Ivonescimab combined with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma patients who failed to respond to prior PD-1 inhibitor combined with platinum-based doublet chemotherapy.

To improve the health of a community, the first step is to identify its most pressing needs.

The Lupus Foundation of America is pleased to honor two leading scientists for their notable contributions to lupus research at the 2022 Evelyn V. Hess Reception held during the American College of Rheumatology convergence 2022 meeting this evening in Philadelphia, PA.